Medicon Valley Alliance and Syneos are pleased to invite you to a Good Morning Meeting on the 13th of March in Copenhagen focusing on:
Navigating the current funding environment and other key challenges in drug development for 2024 and beyond.
An overview of the recent dynamic environmental, economic, regulatory and payer developments which are creating complex and interwoven challenges the global current healthcare has to overcome in order to be successful in the future.
At Syneos Health, we have been developing, planning and preparing for these current and future challenges to ensure we are best placed as a trusted partner in this evolving landscape of drug development, thus helping to bring these new innovations to patients who require them as expediently as possible.
Date: Wednesday 13th of March 2024
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
Program
| 08:30 | Networking, registration, and light breakfast |
| 09:00 | Welcome David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 09:05 | Welcome and Introduction to Syneos Health Bharat Chudasama, VP, Strategic Enterprise Partnerships, EU Paul Holmes, MD, Syneos Health EU Consulting Chris Ponty, VP – Syneos One Asset Development Lead |
| 09:15 | The do’s and don’ts to be fundable in 2024 and beyond Bharat Chudasama – Syneos Health |
| 09:30 | How can Syneos Health better support growing R&D Biotech Companies navigate the current environmental and funding challenges? Chair: Bharat Chudasama, VP, Strategic Enterprise Partnerships, EU Speaker 1: Paul Holmes, MD, Syneos Health EU Consulting Speaker 2: Chris Ponty, VP – Syneos One Asset Development Lead |
| 10:00 | Q&A session |
| 10:15 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Bharat Chudasama, Asset Strategy and Portfolio Leader, Vice President, Syneos One Bharat has more than 22 years of experience in the pharmaceutical and biotech sector, primarily in Oncology and Rare Diseases, working across a number of commercial and product development leadership roles including market access & pricing and commercialisation roles for leading blue-chip pharmacos. His roles have spanned across strategic geographies from US, Europe to the Emerging Markets, working with both, above-country and in-market teams on the optimal product development strategy and implementation plans that drive the overall performance and success of the product(s) and the respective companies. His experience has involved leading, as well as being part of cross-matrix teams, for more than 20 ground-breaking oncology asset launches over the years across multiple indications focussing on the asset’s overall development and manage its lifecycle, as well as dealing with the myriad of regional and localised issues that arise from the implementation of the go-to-market strategy. The breadth of his experience and understanding over the years, ensures he is able to balance the strategic direction for an asset / portfolio, with the operational excellence required to deliver commercially. In summary, he has built his reputation as a trusted partner and subject matter expert based on his passion, extensive experience and deep understanding of oncology, healthcare, market access and commercialisation, coupled with the ability to build long term credible relationships, working together on the end goal to deliver optimal success. |
 |
Paul Holmes, Managing Director, Syneos Health Consulting – Commercial Advisory Group Paul Holmes, PhD, brings almost 20 years of experience in the healthcare industry and assists clients of Syneos Health Consulting’s Commercial Advisory Group. He is passionate to support emerging life science organizations achieve developmental and commercial objectives, holding expertise in product development strategy and commercialization. Within Consulting Paul has led over 145 successful project engagements supporting start-up to top pharma and med-tech companies plan for success. His specialty areas of focus include indication strategy, target product profile optimization, and commercialization strategy. Prior to joining Syneos Health Consulting, Dr. Holmes spent 7 years at Becton, Dickinson and Company as a selected participant in their technical leadership accelerator program for product development. Prior to that he held two postdoctoral research positions at Rutgers University, in The New Jersey Center for Biomaterials, and at DSM Research in The Netherlands, each focused on eliciting a controlled biological response at biomaterial interfaces. Paul holds a PhD in chemistry and earned his BSc (Hons) in chemistry from Heriot-Watt University in Scotland. |
 |
Chris Ponty, Vice President, Syneos One, Syneos Health Chris is an Asset Strategist within Syneos One. Before joining Syneos 3 years ago Chris spent over 25 years in the pharmaceutical industry including leadership positions in commercial operations, sales and marketing and market access.Recent roles include: Marketing Lead, Commercial Integration, Syneos Health EU and Canada Marketing Director for Diabetes MSD (Merck &Co) EU and Canada Market Access Lead for Diabetes and Alzheimer’s MSD (Merck & Co) Business Unit Director, Hospital and Specialty Care MSD UKEducation: Chris holds a BSc (hons) from the University of the West of England and a graduate diploma in marketing from Bristol Business School |
| Organized by | In collaboration with |
 |
 |